Health Canada has granted approval for medical imaging firm MolecuLight’s diagnostic medical imaging device, MolecuLight i:X, to treat chronic wounds.

The handheld fluorescence imaging device provides real-time visualisation of bacteria in chronic wounds, and captures images like a point-and-shoot digital camera.

The device allows clinicians to effectively analyse the bacterial condition of chronic wounds with no patient contact or contrast agents.

MolecuLight founder Dr Ralph DaCosta said: "Canadian clinicians will now have a powerful new tool for more objective assessment of wound bacterial status and better antimicrobial treatment decision making."

"We will now be able to offer clinicians real-time diagnostic information about bacterial load at the bedside."

It also helps to quickly and easily visualise and precisely target clinically important bacteria in and around chronic wounds in real-time at the bedside, helping with targeted and precise treatment plans.

Bacteriological information provided by the device will help clinicians decide whether patients can be treated in a hospital, long-term treatment setting, at home, or in rural areas through telemedicine networks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Clinical trials with MolecuLight i:X, including 180 patients, showed the device improved sample quality, healing rates, screen for high levels of bacteria and detect wound subsurface heavy bacterial load and subclinical local infection in patients.

MolecuLight CEO Craig Kennedy said: "This is a historic day for wound care. We will now be able to offer clinicians real-time diagnostic information about bacterial load at the bedside."

The company is involved in developing fluorescence image-guidance solutions to provide new information about bacterial wounds for better diagnostic and treatment decisions.

Image: MolecuLight i:X imaging device. Photo: courtesy of PRNewswire / MolecuLight.